FAS and hyperlipidemia: Ou et al. administered 10, 20, and 50 mg/kg BW of Mel to hamsters with HFD-induced hyperlipidemia, and found that Mel treatment decreased the activities of the ACC and FAS lipogenic enzymes, and increased the mRNA levels of the CPT-1 lipolysis enzymes, while reducing the hepatic TC and TG contents, thereby, decreasing serum TC, TG, and low-density lipoprotein cholesterol (LDL-C) levels [56].